Laekna Limited

2105 · HKEX · China

Public Market Listing

2105HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Laekna Limited are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(3 total)
3Total Assets
0Approved
1Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
AKT (inhibitor)Small molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 2
Activin receptor type IIA (ActRIIA)Monoclonal antibody
Obesity
Phase 1
Activin receptor type IIB (ActRIIB)Monoclonal antibody
Obesity

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

11 August 2026Filing acceptedAfuresertib (GSK2110183)China NMPA accepts afuresertib NDA
CN, NMPA · Laekna · Source ↗
15 April 2026Topline resultAfuresertibAFFIRM-205 Phase 3 (NCT04851613) met its primary endpoint of PFS
Laekna · Source ↗
30 June 2025Filing submittedLAE103IND application submitted to FDA for LAE103
US, FDA · Source ↗

Financial reports

Quarterly & interim (3)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-H1$22M$14M$139M+ $27M short-term inv.$0.2Mreport ↗
View 2 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1——$104M—report ↗
2024-H1——$89M—report ↗

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$15M$35M$177M+ $2.7M short-term inv.$8.0Mreport ↗
View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY——$110M—report ↗